LB1. Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial

BACKGROUND: Remdesivir (RDV) is a potent nucleotide prodrug inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase that has demonstrated efficacy in the treatment of patients hospitalized with moderate to severe COVID-19. This Phase 3 (GS-US-540–9012) double-blind, placebo-controlled study compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Hill, Joshua A, Paredes, Roger, Vaca, Carlos, Mera, Jorge, Webb, Brandon J, Perez, Gilberto, Oguchi, Godson, Ryan, Pablo, Gerstoft, Jan, Brown, Michael, Schiffer, Joshua, Brown, Samuel, Katz, Morgan, Ginde, Adit A, Camus, Gregory, Porter, Danielle P, Hyland, Robert H, Chen, Shuguang, Juneja, Kavita, Osinusi, Anu, Duff, Frank, Gottlieb, Robert L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Late Breaker Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644260/
http://dx.doi.org/10.1093/ofid/ofab466.1642

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644260/
http://dx.doi.org/10.1093/ofid/ofab466.1642

Ejemplares similares